Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 84 SaxendaⓇ now launched in 25 countries SaxendaⓇ value share of anti-obesity medications in selected countries Mexico Germany 100% Australia Italy USA Brazil UAE 80% 79% 60% Canada DKK Denmark million 52% Spain 2,000 4% 86% 1,600 72% 52% 1,200 47% Countries with highest Saxenda® sales in 20171 SaxendaⓇ value market share SaxendaⓇ volume market share 40% 40% 800 30% 19% 20% 400 14% 30% 4% 86% 14% 79% 74% 6% 43% 6% 0% 0 USA 05 10 15 20 Months from launch 25 30 Brazil Canada Australia UAE Source: IQVIA (formerly IMS) Nov 2017 Note: The market for anti-obesity medication varies significantly in size between countries changing diabetes® 1 Reported sales for the full year 2017 Source: IQVIA (formerly IMS) MIDAS, Nov 2017

View entire presentation